B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and lowers the price target from $620 to $613.
B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and lowers the price target from $620 to $613.